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Abstract
We present a hypothetical case study to examine the use of a next-generation
framework developed by the Genetic Toxicology Technical Committee of the
Health and Environmental Sciences Institute for assessing the potential risk of
genetic damage from a pharmaceutical perspective. We used etoposide, a geno-
toxic carcinogen, as a representative pharmaceutical for the purposes of this case
study. Using the framework as guidance, we formulated a hypothetical scenario
for the use of etoposide to illustrate the application of the framework to pharma-
ceuticals. We collected available data on etoposide considered relevant for
assessment of genetic toxicity risk. From the data collected, we conducted a
quantitative analysis to estimate margins of exposure (MOEs) to characterize the
risk of genetic damage that could be used for decision-making regarding the
predefined hypothetical use. We found the framework useful for guiding
the selection of appropriate tests and selecting relevant endpoints that reflected
the potential for genetic damage in patients. The risk characterization, presented
as MOEs, allows decision makers to discern how much benefit is critical to bal-
ance any adverse effect(s) that may be induced by the pharmaceutical. Interest-
ingly, pharmaceutical development already incorporates several aspects of the
framework per regulations and health authority expectations. Moreover, we
observed that quality dose response data can be obtained with carefully planned
but routinely conducted genetic toxicity testing. This case study demonstrates the
utility of the next-generation framework to quantitatively model human risk based
on genetic damage, as applicable to pharmaceuticals.
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1 | INTRODUCTION
The testing of pharmaceutical drug candidates for the potential to
cause genetic damage has been generally consistent for several
decades. Pharmaceuticals are typically evaluated for the ability to
cause gene mutations or chromosome damage in vitro prior to initia-
tion of clinical trials in small groups of healthy volunteers or patients.
In addition, in vivo tests in rodents for chromosome damage are
required prior to larger clinical trials. These studies (the standard test-
ing battery for pharmaceuticals) are required by regulatory guidelines
(ICH, 2009a, 2011) and positive (genotoxic) pharmaceuticals in these
tests are viewed to have the potential to increase cancer risk or cause
genetic damage to germ cells. Conclusions from tests such as bacterial
mutation (e.g., Ames test) and in vitro or in vivo chromosome aberra-
tions or micronuclei are typically binary, with a yes/no outcome. Tra-
ditionally, these tests have been well-suited to identify the hazard of
possible genetic damage, particularly for direct DNA damaging agents.
However, such a battery type of approach might not always be appro-
priate to detect the broad range of potential genetic damage.
As more has been learned about the structure–activity relation-
ships and chemical motifs that impart genetic damage, medicinal
chemists have learned to avoid chemical moieties that result in posi-
tive genetic toxicity results while maintaining desirable pharmaceutical
properties. However, some pharmaceuticals, like etoposide, demon-
strate an efficacious mechanism of action that derives clinical benefit
via a genotoxic mode of action (e.g., binding to topoisomerase II), lead-
ing to double-strand breaks (DSBs) (Caldecott et al., 1990).
Genetic damage has been established as a potential contributor to
health issues/disease beyond cancer. Modes of action (MOAs) leading
to genetic damage can play a key part in understanding disease progres-
sion and/or susceptibility (Dearfield et al., 2017). Beyond hazard identi-
fication, an understanding of the MOA and an assessment of genetic
damage may allow for the identification of levels below which exposure
to a chemical or pharmaceutical may pose an “acceptable” risk in rela-
tion to the expected benefits. Such levels could be estimated based on
the so-called genetic toxicology “point of departure” (PoD), to which
uncertainty and safety factors are applied. Such new approaches for
characterization of the broad range of potential genetic damage allow
for identification and understanding of diverse MOAs, which may then
be applied to risk assessment and regulatory decision-making.
For genetic toxicology risk assessment, the next-generation test-
ing strategy developed by the Health and Environmental Sciences
Institute (HESI) Genetic Toxicology Technical Committee (GTTC)
involves a systematic and flexible approach for assessing the risk of
genetic damage due to exposure to chemical substances (Dearfield
et al., 2017). It places greater emphasis on estimating the potential risk
of a substance if and when people are exposed rather than applying
genetic toxicity testing data only for hazard identification.
The next-generation testing strategy is a generic approach applica-
ble to a wide range of chemicals. For the present case study, we use
etoposide to evaluate the applicability of the strategy for a pharmaceuti-
cal, a chemical that is intended for human exposure. The GTTC recently
published a similar case study using benzene to study the applicability of
the approach for an industrial chemical (Luijten et al., 2020) where
human exposures are unintentional. Per the benzene example, we used
a retrospective approach for etoposide. Rather than generate a compre-
hensive literature review, the objective was to determine if the next-
generation risk assessment strategy could serve as a useful framework
to collect required data for the identification and characterization of
genotoxic hazard of a pharmaceutical. Hazard characterization included
dose–response analysis and derivation of a PoD resulting from genetic
damage which could lead to mutagenic and clastogenic outcomes.
2 | ETOPOSIDE AS A CASE STUDY
The topoisomerase II inhibitor etoposide is an anticancer agent that
has been evaluated in numerous genetic toxicity tests (IARC, 2000,
2012). Administration has been associated with secondary leukemia
following therapeutic treatment (IARC, 2000, 2012). An adverse out-
come pathway (AOP) describing infant leukemia resulting from chemi-
cal exposures was developed using the analogous etiology of
secondary acute leukemia from etoposide therapy (Pelkonen
et al., 2017). Given the wealth of readily available historical data,
including studies representative of a pharmaceutical genotoxicity
approval package, etoposide was selected as a case example to evalu-
ate the applicability of the next-generation testing strategy.
The next-generation testing strategy provides a framework in
which a series of steps allows for an evaluation of a chemical's genetic
toxicity risk potential in a logical, and structured manner (Table 1).
The steps first outline the problem formulation, including defining the
exposed population, available information, and a description of the
data needs to appropriately evaluate risk. Existing data are then
assembled to build a knowledge base and create a biological argument
for relevant testing. Once testing is performed and relevant datasets
are identified, a quantitative analysis is performed to estimate the
POD, which is then employed in a human risk assessment, resulting in
risk characterization—a genetic toxicology risk assessment—for poten-
tially exposed individuals. This assessment may then be used for risk
management and regulatory decision-making.
The retrospective analysis of etoposide literature data included
standard genetic toxicology tests required for pharmaceutical develop-
ment, per ICH S2R1 (ICH, 2011), as well as additional genotoxicity end-
points. Following the compilation of literature data, the next-generation
testing strategy framework (Table 1) was applied to a select set of stud-
ies. This stepwise, objective treatment of the data approximated a sce-
nario of genetic toxicologists evaluating a novel small molecule
pharmaceutical candidate during drug development. We demonstrate
that application of the framework enabled consideration of test data
beyond the standard ICH S2R1 pharmaceutical test battery
(ICH, 2011). The appropriateness of the strategy was evaluated and
modifications/improvements that could be applied for pharmaceutical
candidates were noted. As this was a hypothetical demonstration using
existing etoposide data intended to demonstrate the use of the frame-
work, this work should not be construed as an endorsement for consid-
eration for this drug for this indication as anticancer monotherapy.
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2.1 | Step 1: Planning and scoping (including
anticipated exposure)
2.1.1 | Planning and scoping
The initial step in the application of the framework is problem scoping
and planning of the work needed to inform management of any risk that
might be associated with a drug. Problem formulation is the systematic
process to guide and direct what scientific questions that must be
addressed in the risk assessment (USEPA, 1998). Thus, the dataset col-
lected may be different for the same chemical depending on the problem
statement (e.g., different exposure scenarios). While planning and scop-
ing outlines the broader questions including considerations such as logis-
tics and costs, problem formulation focuses on the more specific
scientific questions regarding the chemical's potential to cause genetic
damage as well as exposure that may be relevant for human risk.
An important consideration for pharmaceuticals is that, in con-
trast to industrial chemicals where human exposure is generally
unintended and without benefit, drugs are administered to derive a
beneficial therapeutic effect. Drug exposure levels in patient
populations would be expected to greatly surpass accidental environ-
mental exposures, requiring consideration of the drug's MOA(s)/thera-
peutic target versus the potential to induce genetic alteration.
Therefore, our evaluation needed to consider the MOAs based on the
intended primary pharmacology of the drug.
Drugs are developed for specific therapeutic indications, typically
with known targets/MOA. Etoposide was evaluated from the hypo-
thetical perspective of a drug candidate under consideration for adju-
vant therapy in curable cancers (see Table 1 for the risk management
issues in this planning/scoping step). Consequently, the data were lim-
ited to retrospective evaluation that generally included select studies/
assays that would be required for a first-in-human (FIH) clinical trial
application. Acknowledging that pharmaceutical candidates being con-
sidered for advanced cancer therapies would not actually require
genetic toxicology testing to advance to FIH clinical trials
(ICH, 2009b), we made the hypothetical assumption that etoposide
was under consideration for an indication less severe than advanced
cancer—one where patients could be cured of their disease. This justi-
fied qualitative evaluation of the data to evaluate the risk benefit of
such a treatment. To constrain the case study, additional literature-
cited mechanisms were considered out of scope for this case study.
2.1.2 | Scoping of anticipated exposure
The treatment population was assumed to be those on an adjuvant
cancer therapy, or chemotherapy used after successful primary ther-
apy (such as surgery) to reduce the risk of recurrence from cancer cells
that may have escaped primary treatment. As adjuvant cancer thera-
pies are expected to have low/negligible risk since the cancer/tumor
TABLE 1 Framework for next-generation risk assessmenta
Step Process Etoposide as case for adjuvant cancer therapy
1 Planning and scoping (incl.
anticipated exposure)
• Identify the relevant regulations in place for etoposide
• Determine the proposed clinical application(s) and the targeted patient population(s)
• Determine the most likely exposure route(s) for etoposide
• Determine how etoposide will be administered (alone or in combination with other drugs/
therapies)
• Determine the category of anticipated exposure
• Begin risk/benefit analysis as patients will be purposely exposed to etoposide
2 Determine expected exposure • Determine expected pattern of exposure for etoposide therapy
• Estimate the projected efficacious level of etoposide exposure for the population group(s) of
concern
3 Build knowledge base • Chemoinformatics: generate data using QSAR software tools; include predictions on possible
metabolites
• Collect available data from relevant in vitro and in vivo toxicity studies
• Collect mechanistic information
4 Create rational biological argument • Based on the knowledge gathered, determine the potential of etoposide for induction of genetic
damage. If so, determine the most likely mechanism(s) underlying this potential
5 Select assays and perform them Used published studies for etoposide (due to retrospective aspect of this case study)
6 Review results Reviewed published studies for etoposide
7 Select appropriate point of departure • Based on the rational biological argument identify relevant dataset(s)
• Conduct quantitative analyses to derive a PoD
8 Estimate acceptable levels for
endpoints of human relevance
• Determine whether it is appropriate to use a nonlinear approach
• Using the derived PoD determine the acceptable level of daily exposure for the population
group(s) of concern
9 Risk characterization • Estimate the risk for humans by applying a MOE approach and comparing the exposure level to
the acceptable level of daily exposure
aBased on the framework described in Dearfield et al. (2017).
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would have already been removed or cured with the primary therapy,
this low/negligible associated risk informed the extent of testing and
review needed for a risk assessment of this exposed population. The
focus on etoposide adjuvant cancer therapy assumed that exposures
were limited to the subset of patients who could derive benefit. While
the framework could encompass wide exposure to consumers, focus-
ing this analysis to a specific disease scenario and specific patient pop-
ulation receiving the therapy restricted the anticipated exposure
concern.
As the exposure scenario was frontline chemotherapy
(e.g., primary therapy such as surgery, followed by the adjuvant ther-
apy of etoposide), and not a second-line therapy, the complication of
previous exposures to additional genotoxic chemotherapies did not
have to be addressed. To avoid complicating variables for this analysis,
we evaluated etoposide as monotherapy (etoposide alone would be
administered) in the adjuvant setting, although etoposide has com-
monly been used in combination therapy.
2.2 | Step 2: Determination of expected exposure
The exposure assessment to a pharmaceutical can encompass a vari-
ety of target populations. Healthcare workers, manufacturing
employees and the general population may be unintentionally exposed
to a drug. In contrast to industrial chemicals (Luijten et al., 2020),
patients are intentionally exposed to pharmaceutical therapies to alle-
viate disease. Unintentional exposure groups may be exposed for brief
periods at low levels through daily work or environmental contamina-
tion. The biologic effects from such exposures provide no benefit.
While many chemicals are studied for potential toxicities to
derive safe worker exposure limits or water quality standards, phar-
maceuticals are relatively unique in that human exposure scenarios
are extensively studied, via analysis of drug exposure levels following
specific dose administration schedules and routes in animals, healthy
volunteers and/or patients. Such data allow for more precise exposure
assessment to determine the conditions in which efficacy is observed.
These levels could be compared to exposures in experimental systems
where genotoxicity occurs. The assumed target population, identified
in the planning and scoping, are individuals with a high cancer cure
rate. Exposure to agents that cause genetic damage in this patient
cohort may therefore represent a different risk compared to other
patient groups, as would be reflected in the risk characterization.
In adults, a typical monotherapy etoposide dosing regimen as pri-
mary treatment can range from 35–200 mg/m2 daily for up to 5 days
(Cancer Care Ontario, 2020; Medscape, 2021). For use as an adjuvant
treatment, a typically cited dose is 100 mg/m2, usually in combination
with another chemotherapeutic (McHugh & Feldman, 2018; Motzer
et al., 2000).
Etoposide can be administered orally or intravenously, with either
short or long infusions for a variety of cancers (IARC, 2000;
McLeod, 1997). Via the oral route, bioavailability is about 50%
(IARC, 2000). Plasma protein binding is about 95% (IARC, 2000). In
general, exposure is linear with increasing dose (Würthwein &
Boos, 2002). The framework encourages collection of absorption, dis-
tribution, metabolism, and excretion (ADME) data for exposures.
Unlike industrial chemicals, ADME properties of drugs are compre-
hensively evaluated during drug development. But in this case study,
for simplicity, we assumed a maximum exposure scenario with an
intravenous dosing regimen, resulting in 100% bioavailability, with dis-
tribution to most tissues in the body, eliminating the need to consider
what fraction of dose is systemically available to cause the observed
genetic toxicity.
2.3 | Steps 3–4: Building the knowledge base and
creation of a rational biological argument for genetic
damage
2.3.1 | Building the knowledge base
The next steps in the framework involve the development of a
knowledge base by collection and consolidation of existing data, and
the creation of a biological argument (Table 1, Steps 5–6). Due to
the retrospective nature of the case study, the knowledge base was
developed in conjunction with a review of compiled in vitro and
in vivo genotoxicity studies. During drug development, standard pre-
clinical in vitro and in vivo genotoxicity test “battery” assays
(ICH, 2011) are a reasonable start for developing the knowledge
base. In addition, in silico examination of other drugs focusing on the
same or similar therapeutic target/MOA is considered extremely
useful for creating a biological argument and for identifying any
needed additional tests.
2.3.2 | Target assessment/assessment of
anticipated MOA
Etoposide antagonizes cell division and inhibits tumor growth, forming
a complex with topoisomerase II and DNA. This complex formation is
covalent and not reversible, preventing re-ligation of the cleaved DNA
double-strand and leading to DSBs (Caldecott et al., 1990). The
increase of DSBs will trigger DNA damage response via yH2AX signal-
ing of DSB and activation of p53. DSB repair, namely homologous and
non-homologous end joining (NHEJ), will cope with the damage
(de Campos-Nebel et al., 2010; Malik et al., 2006; Smart et al., 2008;
Sung et al., 2006). Exhausting repair capacity and damage accumula-
tion ultimately leads to activation of apoptosis and cell death. Rapidly
dividing cells like cancer cells will be more sensitive to this activity
than resting cells, resulting in tumor cell death. However, organs con-
taining rapidly dividing cells such bone marrow may also suffer.
Chronic toxicity may also result from error prone DNA repair like
NHEJ and accumulation of mutations resulting in increased cellular
senescence and impaired cellular function in surviving cells. A prelimi-
nary AOP describing how topoisomerase II inhibition leads to
increases in chromosome breaks and rearrangements and/or gene
mutations is described in Sasaki et al. (2020).
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2.3.3 | Creation of a rational biological argument
for testing
Based on the intended pharmacological activity of etoposide and the
preliminary AOP, testing that allows for assessment of chromosomal
breakage events would be most valuable. Further relevant tests
include genotoxicity studies detecting the relevant DNA damage, in
this case DSBs, and studies which measure any key events for genetic
damage, such as the γH2AX assay, in vivo complex of enzyme assays
measuring DNA-topoisomerase II covalent binding, supercoiled DNA
cleavage/ relaxation assays and decatenation assay (Nitiss
et al., 2012; Sahai & Kaplan, 1986).
2.4 | Steps 5–6: Selecting and performing assays;
reviewing results
Since etoposide is an extensively studied drug, this exercise examined
selected studies that have been performed and were deemed appro-
priate to test the possible genetic adverse effects resulting from ther-
apeutic anticancer treatment. The results of these studies were
subsequently reviewed to identify those studies that offered the most
relevant information to characterize the genotoxic potential of
etoposide. Appropriate positive genotoxicity results, that would typi-
cally be generated in a drug development setting, were selected to
identify a PoD for a quantitation of any possible risk to exposed
patients, outside of its intended therapeutic use.
It should be clarified that to demonstrate the use of the frame-
work, it was easier to use an example drug with plenty of existing
data. However, the amount of data found is much more than would
typically be generated for a drug candidate, and thus only select stud-
ies were chosen for consideration for quantitative analysis. Similarly,
this work is not meant to represent a review of all genotoxicity and
mechanistic research available for etoposide.
2.4.1 | In silico results: (Q)SAR and read-across
evaluations
Generally, there is little human data available for a pharmaceutical
early in the development of a class of drugs. An in silico examination
of a similar marketed product could provide insights into the likeli-
hood of genetic damage from exposure to a novel drug of the same
class. Using such in silico techniques are now commonplace in drug
discovery and development, providing early insights into possible
adverse effects. This in silico exercise examined etoposide as a novel
candidate drug in several models.
(Q)SAR ([Quantitative] structure–activity relationship) models can
identify structural features associated with various toxic effects
including genotoxic potential. “Read-across” is another useful tool to
identify potential toxicities. This approach relies on structural analogs
with experimental data to extrapolate potential genotoxic liabilities
for an untested compound. These types of assessments are often
conducted to support early drug development prior to conducting piv-
otal animal studies. Both chemists and toxicologists can utilize these
tools to help establish an optimal testing strategy.
The potential genotoxicity of etoposide was evaluated in two
commonly used models (Table 2). A review of the (Q)SAR data indi-
cated that etoposide was part of the model training sets, highlighting
the difficulty in retrospectively applying (Q)SAR models to analyze a
known genotoxicant. Though etoposide was found in the training sets,
we conducted the (Q)SAR analysis as it would have been done if
etoposide was an “unknown” to the training set.
Etoposide was predicted negative for bacterial mutagenicity in
most Ames strains but likely positive with Escherichia coli or Salmonella
typhimurium strain TA102, and predicted positive for in vitro mutation
in mammalian cells and for clastogenicity. The two models used dif-
fered in their prediction for in vivo clastogenicity.
In addition to performing (Q)SAR analysis for etoposide, a struc-
tural analog search was conducted. Teniposide, another topoisomer-
ase II inhibitor with a known genetic toxicity profile, was identified.
Overall, the interpretation of teniposide (Q)SAR predictions (not
alerting for mutagenesis, alerting for clastogenesis in vitro and in vivo;
possible DNA intercalation) and teniposide genetic toxicity data, along
with our informed analysis of the MOA, indicated that etoposide
could present a genotoxic risk through gene mutations or chromo-
some damage, to patients with potentially chronic or curable cancers.
Based on the intended MOA for therapeutic use and the indications
from the in silico results, clastogenicity is a very likely primary mecha-
nism for etoposide's risk.
TABLE 2 Commonly used models for in silico (Q)SAR evaluation











































aEtoposide identified in the test reference set.
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2.4.2 | In vitro results
After identifying genotoxicity flags in in silico systems, our assumed
scenario of an adjuvant oncology therapy indication would typically
be followed by a series of routine in vitro genetic toxicity tests (usu-
ally, a gene mutation test in bacteria and a chromosome damage test
in cultured mammalian cells). Regulatory guidelines identified in the
planning phase of the framework required these tests regardless of
the (Q)SAR and read-across findings for nonlife-threatening indica-
tions (ICH, 2009a, 2011). In addition, while the step “Creation of a
Rational Biological Argument for Testing” identified chromosome
damage tests as pertinent to etoposide based on its MOA, these regu-
latory guidelines generally require testing for gene mutations prior to
administering drugs to clinical trial subjects. A summary of the data
from the reviewed in vitro genetic toxicology tests are depicted in
Table 3.
In bacterial reverse mutation tests, etoposide treatment resulted in
negative or weak-positive gene mutation responses in S. typhimurium or
E. coli in the presence or absence of an exogenous metabolic activation
system (Ashby et al., 1994; Gupta et al., 1987; Matney et al., 1985;
Nakanomyo et al., 1986). In mammalian cell mutation tests, etoposide
increased gene mutation frequency in Chinese hamster ovary (CHO)
and human T-lymphoid cells (larger deletions) at the hypoxanthine-
guanine phosphoribosyl transferase (HPRT) and adenosine kinase (ADK)
loci, and induced DNA strand breaks and sister-chromatid exchanges
(Chen et al., 1996; Gupta et al., 1987). Increased gene mutations
observed at the thymidine kinase locus of L5178Y cells were mostly
small colony mutants, indicating clastogenic origin (Ashby et al., 1994).
In a recent in vitro study for mutation in the phosphatidylinositol glycan
class A (Pig-a) gene, etoposide did not increase the mutation frequency
(% of GPI[] cells) in L5178Y mouse lymphoma cells (confirmed using
Sanger sequencing), suggesting that gene mutation mechanisms are not
the primary MOA for etoposide under in vitro conditions (David
et al., 2018).
Etoposide has clastogenic properties in a number of in vitro stud-
ies (CHO, L5178Y, HepG2, TK6 cells) at concentrations ranging from
40 ng/ml (Ashby et al., 1994; Boos & Stopper, 2000; Doherty
et al., 2011; Fellows et al., 2008; Hermine et al., 1997;
Larripa et al., 1992; Lynch et al., 2003; Thougaard et al., 2014;
Westerink et al., 2011; Diaz et al., 2007; Smart et al., 2008; Tilmant
et al., 2013). Human cells are more sensitive to etoposide compared to
mouse cell lines in in vitro micronucleus tests and apoptosis studies
(Laingam et al., 2008). The micronuclei induced by etoposide were
shown to be a result of both clastogenic (61%–84% were kinetochore-
negative) and aneugenic (26%–39% were kinetochore-positive) activity
in CHO cell lines (V79-4, irs-1, and irs-3) (Hermine et al., 1997).
Overall, in vitro testing indicated that etoposide has the potential
to cause chromosomal damage, and while some individual tests
showed positive results, the weight of evidence shows etoposide is
less likely to cause gene mutations.
2.4.3 | In vivo results
A summary of the responses from the in vivo genetic toxicology
tests reviewed is shown in Table 4. Consistent with in vitro results,
etoposide induced a small but nonsignificant increase in Tk, but not
Hprt mutation frequency in mice at doses up to 10 mg/kg
(Dobrovolsky et al., 2002; Turner et al., 2001). As per the Trans-
genic Rodent Assay Information (TRAiD) database, etoposide
yielded negative results in bone marrow, liver, and lung and when
dosed at 25 mg/kg/d for 8–12 weeks via the intraperitoneal route
in the mouse in transgenic (lacZ; i.e., Muta™Mouse and lacZ plasmid
mouse) rodent mutation assay (Lambert et al., 2005). It should be
noted, that the TRAiD database contains a majority of experiments
which were conducted in the 1990s and early 2000s, before the
standardization of the OECD TG488 test guideline (OECD, 2020).
Consistently, in Sprague–Dawley rats, following a single intrave-
nous dose of 5, 10, or 20 mg/kg, etoposide was negative in bone
marrow Pig-a and PIG reticulocyte (PIGRET) assays (Kimoto
et al., 2016).









Ashby et al. (1994),













et al. (1990), Ashby
et al. (1994),
Berger
et al. (1996), David
et al. (2018)






























Sjöblam et al. (1994),
Slob, 2002)
NICOLETTE ET AL. 517
Etoposide was shown to induce DNA damage in in vivo comet
studies. In male B6D2F1 mice, etoposide increased DNA damage at
dose levels up to 50 mg/kg (Turner et al., 2001). Similarly, in male
Sprague–Dawley rats, at 5 and/or 50 mg/kg following a single dose,
etoposide induced a positive response in the comet assay in whole
blood, bone marrow, liver, and intestine at the 1-h timepoint, and in
TABLE 4 Summary of in vivo nonclinical genotoxicity testing of etoposide
Assay (species/strain) Results Dose level, route, duration Reference
Gene mutation
Inconsistent and negative results
TK+/ male and female mice
(C57BL/6 background)
No statistically significant increase in
Hprt or Tk mutant frequency
1 and 5 mg/kg i.p., single dose Dobrovolsky et al. (2002)
B62DF1 mice and APRT
heterozygous mice
No statistically significant increase in
Hprt mutant frequency. Significant
increase in Aprt at 1 mg/kg, but not
at 10 mg/kg. FISH analysis
suggested mitotic recombination or
chromosome loss and duplication as
the mechanism of loss of
heterozygosity in Aprt clones





125 mg/kg i.p., five applications,
sampling up to 35 days
1 mg/kg i.p., single dose, sampling on
Day 14
Lambert et al. (2005),
Tinwell et al. (1998)
Pig-a, PIGRET (Male Sprague
Dawley rat)
No statistically significant increase in
mutant frequency






(Male Sprague Dawley rat)
Significant increases in mean tail
moments at 1 and 4 h
5 and 50 mg/kg i.p., single dose Godard et al. (1999)
B62DF1 mice Significant increase in comet tail
moments at 1 h
1 or 100 mg/kg mg/kg i.p., single
dose
Turner et al. (2001)
Male Long–Evans rats Significant increases in comet tail
moments at 1.5 h, but not at 3 h
25 mg/kg, gavage, single dose Spronck and Kirkland (2002)
Chromosome damage
Swiss albino mouse Significant increase in clastogenicity
at 6 and 12 h
5, 10, 15, and 20 mg/kg .p., single
dose
Agarwal et al. (1994)
B62DF1 mice Significant increase from 0.1 to
1 mg/kg
0.1 to 16 mg/kg i.p., single dose; 24 h
exposure
Turner et al. (2001)
MNT (male
(102/ElxC3H/El) F1 mice) and
FISH analysis
Significant increases in clastogenic
and aneugenic responses
1 mg/kg i.p., single dose Attia et al. (2003)
Male and female Swiss albino
mice
Significant increases in chromosomal
aberration in females and males at
20 mg/kg at 24 h
Significant increases in in vivo MNT
in males and females at 15 and
20 mg/kg at 30 h
10, 15, or 20 mg/kg i.p., single dose Choudhury et al. (2004)
CD-1 mice Significant increases in in vivo MNT 0.75 to 6 mg/kg Nakanomyo et al. (1986)
CD-1 mice Significant increases in in vivo MNT
mainly due to whole chromosome
lagging in spermatids at 24 h
25 mg/kg i.p., single dose Kallio and Lähdetie (1993)
Male Sprague–Dawley rats Significant increases in MNT in bone
marrow and peripheral blood at all
doses
14.3, 28.5, 57, and 114 mg/kg,
gavage, 2 days
Fiedler et al. (2010)
Male and female F344 rats Significant increases in in vivo MNT 1.14, 11.36, and 57 mg/kg, gavage,
14 days
Garriott et al. (1995)
Male Long–Evans rats Significant increases in in vivo MNT 1 mg/kg, gavage, single dose Spronck and Kirkland (2002)
Wistar rats [Crl:WI (Glx/Brl/
Han)]
Significant increases in in vivo MNT
only at 25 mg/kg
12.5 and 25 mg/kg, gavage, four
doses
Tilmant et al. (2013)
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bone marrow and intestine at the 4-h timepoint. In contrast, kidney
and thymus were negative in this assay (Godard et al., 1999; Kirkland
et al., 2019).
In in vivo cytogenetic studies, etoposide has been shown to be a
clastogen at high dose levels, as well as at lower, clinically relevant
exposures. At doses from 5 to 20 mg/kg etoposide induced a dose-
dependent, significant increase in bone marrow clastogenicity in Swiss
albino mice when administered via intraperitoneal administration
(Agarwal et al., 1994; Choudhury et al., 2004). Similarly, doses from
0.5 to 10 mg/kg induced a dose-dependent increase in sister chroma-
tid exchanges. An increase in cell cycle time, as measured by average
generation time, was also observed, with cells in the S-phase being
specifically targeted and blocked in the late S/G2 transition (Agarwal
et al., 1994). In a subsequent single dose study at clinically relevant
exposures, etoposide induced a significantly higher number of chro-
mosomal aberrations and micronuclei in the bone marrow of male and
female mice at the highest dose (20 mg/kg) tested (Choudhury
et al., 2004). In the Fisher 344 rat, Garriott and coworkers reported a
positive micronucleus response at 57 mg/kg (5x the clinical dose, on
an equivalent mg/kg basis), following 14 days of repeat dose treat-
ment (Garriott et al., 1995). In both the mouse and rat, following a sin-
gle dose (mouse) or two repeat daily doses (rat) of etoposide,
micronuclei were observed in spermatids at the diplotene diakinesis,
late pachytene, preleptotene, and diplotene-diakinesis stages (Kallio &
Lähdetie, 1993, 1997; Lähdetie et al., 1994). In addition to somatic cell
clastogenic effects, etoposide has been shown to induce aneuploidy
and cell cycle arrest in male Balb/c mouse germ cells. Following a sin-
gle intraperitoneal dose of 20 mg/kg etoposide, a statistically signifi-
cant increase in CREST positive micronuclei were observed (Kallio &
Lähdetie, 1997).
Taken together, the reviewed studies (Tables 3 and 4) suggest
that the primary genotoxic mechanism for etoposide is chromosome
damage. None of the reviewed studies noted drug exposure measure-
ments, therefore, exposure-response assessment data could not be
evaluated.
2.4.4 | Review of results
While Tables 3 and 4 represent a summary of research that has been
conducted with etoposide for evaluation of genotoxicity, not all of
these tests would be necessary during drug development. Thus, bac-
terial reverse mutation tests may indicate the need for an in vivo gene
mutation, such as the lacZ studies in transgenic rodents. Once deter-
mined as negative, no further in vivo gene mutation assays would be
conducted. After obtaining positive results in an in vitro chromosomal
aberration test, in vivo micronucleus testing would be conducted, usu-
ally in one species of rodent. A typical testing workflow for genetic
toxicology support for a pharmaceutical and follow-up testing needed
based on the genotoxicity of etoposide is shown in Table 5.
Studies shown in Table 5 may be the only assay types needed to
determine that etoposide causes chromosome damage and with an
appropriately designed study, a dose–response analysis can be
conducted to establish a PoD for this endpoint. With this latter sum-
mary in mind, analysis of the etoposide data set was progressed to
Steps 7–9 of the framework.
2.5 | Steps 7–8: Selecting an appropriate PoD and
estimating acceptable levels for endpoints of human
relevance
From the reviewed studies, the in vivo rat study described in Garriott
et al. was selected for quantitative analysis as it demonstrated positive
results in a bone marrow micronucleus assay (an appropriate assay
given the known MOA of etoposide) (Garriott et al., 1995). The study
also provided appropriate data to model the dose–response relation-
ship in an in vivo system. A PoD for estimating a possible “safe” dose
for a healthy clinical subject can be determined from the dose–
response analysis. The selection such a dose for clinical trials would
be a primary objective for the FIH trial for an adjunct oncology indica-
tion. With such an estimated dose, the probability of adverse genetic
toxicity is by design reduced as much as possible while ensuring the
safety of the therapy with an efficacious treatment.
2.5.1 | Quantitative analyses
The studies described by Garriott et al. (1995) using male and female
F344 rats were analyzed (Table S1). The study design is representative
of a typical pharmaceutical study that includes a micronucleus end-
point on a 2-week general toxicity study, as well as providing
dose–response data of low, medium, and high responses of micronu-
cleus formation. These datasets were modeled using Benchmark
TABLE 5 Typical genetic toxicology assessment for































positive risk of chromosome
damage
aTissues studied: bone marrow, liver, and lung (Lambert et al., 2005).
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Dose (BMD) analysis in PROAST (PROAST; www.rivm.nl/proast;
Slob, 2002). We applied the covariate approach, where the model is
fitted to a combination of datasets with dataset as a covariate, to
improve the precision in the estimated BMDs (reflected by the width
of the BMD confidence interval (CI) (Slob & Setzer, 2014; Wills
et al., 2016). Models with additional parameters are only accepted if
the difference in log-likelihood exceeds the critical value at p < 0.05
(Slob & Setzer, 2014). In this way, it can be established which model
parameters need to be estimated for each subgroup, and which
parameters may be considered as constant among the subgroups of a
combined data set. In general, it was assumed that the maximum
response (parameter c) and log-steepness (parameter d) (i.e., the two
shape parameters) were equal for all response curves, while parame-
ters for background response (parameter a), potency (parameter b)
and var (i.e., within group variation) were examined for being covariate
dependent (Wills et al., 2016). Application of the covariate BMD anal-
ysis showed that the dose responses for males and females were
highly similar, which was reflected in the overlapping BMD CIs
(Figure 1, Table 6). Using a critical effect size (CES) of 50%, as rec-
ommended for in vivo micronucleus data (Zeller et al., 2018) instead
of the default value of 10% (EFSA, 2005), resulted in BMDL (i.e., the
lower 90% CI of the benchmark dose) values of 2.89 and 5.82 mg/kg
body weight for males and females, respectively (Table 6).
A similar analysis was conducted on data from a study reported
by Fiedler et al. (2010), in which etoposide was tested in male
Sprague–Dawley rats. In this study, the response for MN% only cov-
ered the medium and higher range, but not the low or very high
response regions (Table S2). Consequently, the resulting BMD CIs
were not as narrow as those obtained using the Garriott data, as
shown by higher BMD CI ratios (Figure S1 and Table S3). Therefore,
we considered the Garriott study more appropriate for our
purposes.
Estimated acceptable levels for endpoints of human relevance
Based on the existing data and analyses, a BMDL50 of 2.89 mg/kg/
day derived for rodents was an appropriate PoD to use as starting
point for estimating allowable human exposure levels. Several
methods exist for deriving a safe exposure dosage from animal data.
In some cases, the PoD can be used in an equation such as seen in
ICH Q3C for residual solvents which includes additional adjustment
factors for determining a safe dose for human exposure such as
adjusting for the test species, the duration of the study used in the
analysis and the severity of the toxicity seen (ICH, 2019). This
approach is often used with exposures to non-mutagenic carcinogens
as impurities in pharmaceuticals (Bercu et al., 2018).
For clinical development, the starting dose is determined by the
regulatory guideline “Estimating the Maximum Safe Starting Dose in
Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers”
(USFDA, 2005) as well as within ICH Guidance (ICH, 2009a).
According to this guideline, the PoD, which could be a no adverse
effect level (NOAEL) in mg/kg or mg/m2, is converted to an equivalent
human dose by converting the animal dosage to equivalent dose
F IGURE 1 Covariate BMD analysis of %MN PCE in male (red line, cross character) and female (black line triangle character) rats from Garriott
et al. (1995), using a CES of 50% (a,b). Results are shown for the exponential and Hill models. The BMDL–BMDU plot from the exponential (top
line) and Hill (bottom line) model are also presented (c). Log10 used for each axis
TABLE 6 Covariate BMD analysis using a CES of 50% was carried
out using PROAST v65.5
BMD confidence interval bounds
MN PCE% MN PCE%
Male Female
BMDL50 (mg/kg) (CES 50%) 2.89 5.82
BMDU50 (mg/kg) (CES 50%) 7.42 15.5
Note: Dose response data from the MN PCE% in male and female rats was
assessed from the Garriot 1995 publication (Garriott et al., 1995). The
lowest BMDL and highest BMDU from the Hill and exponential models
(Figure 1) are presented.
Abbreviations: BMDL, lower confidence limit of BMD; BMDU, upper
confidence limit of BMD.
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based on body surface area. To apply this conversion, Table 1 of the
guideline shows that we can first convert the rat PoD in mg/kg to a
human equivalent mg/kg by dividing by 6.2 (or multiplying by 0.16):
2.89 mg/kg in rat / 6.2 = 0.47 mg/kg human equivalent dose.
Often for cancer drugs like etoposide, human dosages are
expressed in mg/m2. Therefore, the human equivalent PoD in mg/kg
could be converted to mg/m2. This is done by multiplying by the Km
which converts mg/kg to mg/m2 for each species shown in Table 1 of
the guideline. For humans, the Km is 37, thus:
0.47 mg/kg  37 = 17.4 mg/m2 (USFDA, 2005).
While micronucleus induction may be monitored clinically, the
assumption is that the effects from genetic damage manifest in such
an assessment would be adverse and irreversible, increasing the risk
to patients. Additional factors may contribute to the derivation of a
starting dose. The US FDA guidance provides a method calculating a
safe starting dose for healthy clinical subject, where our case example
would be applied to patients who have curable cancer. Some leeway
may be given under this situation to increase the starting dose level.
Likewise, the dosing schedule may influence the risk characterization.
If the adjuvant therapy were given less frequently than daily (for
example once a week or once every other week) the daily burden
from exposure to the genotoxic drug may be reduced such that a
higher starting dose may be acceptable. As the dose increases during
clinical trials, it may exceed the dosage where genetic damage would
occur. Thus, the risk from the dose range expected to be administered
along with other considerations needs to be considered in relation to
the expected efficacious doses to determine if advancing to the clinic
is feasible.
2.6 | Step 9: Risk characterization
To characterize the risk toxicities of a pharmaceutical to humans, the
expected human exposure is compared to the exposure or projected
exposures that causes the hazard in each treatment condition. Risk
characterization for pharmaceuticals considers additional factors, such
as the benefit the exposure may provide the patient.
As the established clinical use of etoposide is treatment and cure
of existing cancer, there is a positive risk–benefit ratio associated with
therapeutic use of this drug. In contrast, use of etoposide alone in an
adjuvant setting would be dependent on whether this drug could be
shown to decrease the risk of recurrent cancer at dose levels associ-
ated with very limited or negligible genotoxic risk. Clinical data, pro-
jections of efficacy, additional/standard treatment options must be
weighed into decisions to advance clinically with such a profile for this
scenario.
F IGURE 2 Diagrammatic
presentations of the calculated
margins of exposure (MOEs) for
the hypothetical etoposide
adjuvant therapy exposure case
study compared to primary use
exposures for etoposide as an
adjuvant and primary therapy.
The MOE in each presentation is
based on the PoD calculated from
the in vivo micronucleus study
discussed in the text (2.89 mg/kg
or 17.4 mg/m2). Units are in
mg/m2 for all diagrams. (a) is a
linear presentation. (b) and (c) are
based on plots from Embry et al.
(2014); see publication for more
detail on plot generation. The
MOE range is shown as a 1:10
ratio (b) and as a 1:3 ratio (c). The
green area represents a more
acceptable MOE, the yellow a
borderline acceptable/
unacceptable MOE, and the red a
less desirable MOE
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In this hypothetical case study based on exposure levels consistent
with adjuvant therapy for cancer patients, the target would be a sufficient
MOE to predict low risk (as seen in Figure 2a). When nonclinical toxicities
are observed, the hope is that an adequate safety margin, that is, MOE,
can be established in the clinical trial. While there are no defined safety
margin requirements for various treatment indications, pharmaceutical
sponsors typically look for at least a 10-fold margin for non-oncology indi-
cations. Due to the life-threatening nature of cancer, margins under 1 can
be acceptable under certain circumstances (ICH, 2009b).
For this hypothetical case, an acceptable MOE range of 3- to
10-fold was targeted (Figure 2) using 2.89 mg/kg (17.4 mg/m2) as the
POD in relation to a 35–100 mg/m2 treatment, representing a range of
typical etoposide doses but limited for the purposes of this case exam-
ple. The plots in B and C of Figure 2 show that the range of etoposide
exposures is probably not large enough (ranges falling in the red zone)
to ensure an adequate margin to safely expose people either for a clini-
cal trial or for intended therapy under this scenario. However, it can be
pointed out to decision makers that the dose(s) intended for this sce-
nario are not far from a possible “acceptable” dose range (yellow zone)
and are under dosing regimens seen with actual etoposide use in cancer
therapies. In this simplified case study, working from the assumption
that an adequate MOE would be needed for the intended population,
the likely outcome from the risk characterization based solely on
genetic toxicity would be that the proposed use of etoposide would
not be generally appropriate. However, risk managers/decision makers
would likely take other factors into account, especially benefits to a
population that needs therapy, and then could decide differently.
3 | EVALUATION OF ETOPOSIDE
AS A PHARMACEUTICAL CASE STUDY—
CONCLUSIONS
The use of etoposide as a hypothetical case study was insightful. The
initial aim was to retrospectively apply the framework and identify
adjustments that could be specifically incorporated for pharmaceutical
applications. Upon review, it became apparent that much of the
framework is already routinely applied during the genotoxicity assess-
ment of pharmaceutical agents. A drug candidate may cause direct
DNA damage and poses a risk to healthy volunteers or patients, so
this concern must be addressed early in discovery and/or develop-
ment phases (planning and scoping); knowledge of the drug target and
possible off-targets effects, structural moieties and reactivity, expo-
sure and distribution, and metabolism are typically gathered to deter-
mine if there could be potential for genetic damage (e.g., for small
molecules, systemically available drugs) or not (e.g., for biological
drugs, small molecules not absorbed) (building a knowledge base).
While the framework does not radically alter the existing pharma-
ceutical industry practices, it does offer a systematic and comprehen-
sive evaluation approach and provides a path for quantitation of risk.
The framework additionally prompts the user to consider a broader
array of testing and information tools beyond the traditional genetic
toxicology test battery approach.
By scoping and planning what data are needed, that is, either neg-
ative results for genotoxicity or an acceptable MOE, we showed how
the framework helped us decide the appropriate testing for the spe-
cific clinical situation as opposed to a default approach for drugs
intended for treatment of cancer patients. As existing data indicated
possible risks for mutation or chromosome damage (Table 3), appro-
priate in vivo studies were identified to address patient risk. An impor-
tant learning was that while current regulatory guidelines provide
suggestions for in vivo testing and study design to support qualitative
conclusions, few of the etoposide literature studies were designed to
generate robust dose–response data. While existing regulatory test
data may be incorporated into the framework, a fundamental shift in
study objectives—to obtain quality data to inform a dose–response
analysis—needs to be incorporated. Although current testing guide-
lines aim to identify genotoxic hazards, this framework encourages
study designs that result in dose–response data that can be used for
quantitative analysis and derivation of genotoxic PODs. Risk charac-
terization and a risk/benefit profile encompassing acceptable expo-
sure safety multiples may then be applied to enable human dosing of
genotoxic drugs, at dose levels that impart acceptable risk/benefit.
While some genotoxicity assays were originally designed for hazard
identification, with the proper dose response data, quantitative analysis
of such data sets is possible. For example, both Fiedler et al. (2010) and
Garriott et al. (1995) explored dosages of 57 mg/kg, with Fiedler
employing doses above and below (114 mg/kg as high dose, with dose
declinations of 50%) given orally for 2 consecutive days. Garriott et al.
included a micronucleus assessment on a 14-day study with a high dose
of 57 mg/kg along with doses of 11.36 and 1.4 mg/kg. MN-PCE
responses to etoposide treatment in the Garriott study provided a
strong dose response (0.1%–8.7% MN-PCE in male rats; 0.14%–1.86%
MN-PCE in female rats) and provided greater confidence in the BMD
calculation with tighter CIs (Table S1, Figure 1) and was subsequently
used in our risk assessment. Data from Fiedler et al. (Table S2) was
assessed for the BMD (Fiedler et al., 2010) however, the dose response
for MN% was only within the medium range (2.3%–4.9% across the
dose range of 14.3–114 mg/kg), not covering the low or high response
regions, and therefore did not provide precise BMD CIs, as shown by
higher BMD CI ratios (Table S3; Figure S1) (Fiedler et al., 2010).
While the review of studies indicated that determination of a
more precise BMD requires a robust dose response, BMD may be
determined from a standard in vivo micronucleus design, provided
that an ample range and number of dose levels are included. This
observation emphasizes the importance of the initial planning and
scoping steps, in which proactive consideration for the type of data
needed to solve the problem must be identified to select the appropri-
ate assay and study design. While the Garriott et al. (1995) experi-
ments were not intended to identify a PoD, the results were
amenable to such an analysis. In vivo genotoxicity studies that offer
an appropriate number of dosing groups and/or target plasma expo-
sures that can be compared to projected efficacious plasma levels
may help provide answers to the problem statement.
In our case study, BMD50 ranges were derived. Human dose
equivalents imparting an acceptable level of genotoxic risk, which still
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imparted efficacious anticancer response, would then be derived.
Assessment of pharmaceutical impurities is an alternative case study
that could produce high BMD50 values which could be controlled by
setting low specification levels. As illustrated by these different sce-
narios, in the planning and scoping step, it is important to consider
possible outcomes and the critical problem statement.
While this exercise was not intended to justify use of etoposide mon-
otherapy and/or represent a real-life clinical indication, this case study
demonstrated the steps and outcomes of this framework for examining
genetic damage with etoposide as a model drug and was an insightful
effort which helped identify the key data among the wealth of available
existing data. Etoposide's well-understood mechanism of action as a topo-
isomerase II inhibitor, and the positive genotoxicity results covering multi-
ple doses both in vitro and in vivo, allowed for derivation of a benchmark
dose. Clarification of the targeted population during planning and scoping
was determined to be crucial step to select/design studies and produce
data that informed risk/benefit for the intended patient population.
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